Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled study to
assess the safety, tolerability, and pharmacokinetics (PK) of IGM-6268 administered
intranasally and intraorally in healthy volunteers and in outpatients with mild-moderate
COVID-19. IGM-6268 or placebo will be administered by intranasal + intraoral spray using a
Teleflex Mucosal Atomization Device Nasal™ Intranasal Mucosal Atomization Device once, or
once or twice each day for 5 days.